18/07/2026
Summarise ENAR Therapy Research results
Research results regarding Electro-Neuro-Adaptive-Regulator (ENAR) Therapy demonstrate its efficacy in pain management and functional rehabilitation, particularly for musculoskeletal disorders:
1. Postmarket Surveillance Findings
A comprehensive postmarket surveillance study evaluated the real-world outcomes of users utilizing the ENAR device:
Pain Reduction: Respondents reported a significant mean pain reduction of 70% following therapy. Between 15% and 20% of users achieved complete pain relief.
Functional Improvement: Users experienced a 62% mean improvement in daily physical functioning.
Medication Reduction: An overwhelming 91% of respondents reported decreasing their medication intake after incorporating ENAR therapy into their regimen.
Primary Applications: The majority of users (76%) utilized the device exclusively for musculoskeletal disorders—most notably back, neck, and shoulder pain—while 16% used it for a combination of musculoskeletal and nonmusculoskeletal complaints.
2. Clinical Trial Evidence
While large-scale clinical trials remain limited, key randomized controlled research has validated its specific utility:
Efficacy Over TENS and Sham Treatments: In a randomized controlled trial focusing on chronic neck pain sufferers, ENAR therapy demonstrated a statistically and clinically significant advantage in both pain reduction and functional improvement when compared directly to standard Transcutaneous Electrical Nerve Stimulation (TENS) and inert sham treatments.
3. Proposed Mechanism of Action
ENAR operates as a hand-held electrostimulator classified as a Class IIa medical device. It utilizes a reflex-biofeedback mechanism to read changing electrical impedance patterns in the skin (referred to as "asymmetry" or "key zones"). The device dynamically alters each consecutive electronic impulse based on the real-time state of the peripheral nervous system, aiming to clear neuroenergy blockages and trigger systemic pain-mediating neuropeptides and hormones.